# Effectiveness and Safety of Enbrel® (Etanercept) in Rheumatoid Arthritis Subjects Who Have Failed Remicade® (Infliximab)

> **NCT00099554** · PHASE4 · COMPLETED · sponsor: **Amgen** · enrollment: 200 (—)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Etanercept

## Key facts

- **NCT ID:** NCT00099554
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 200 (—)
- **Last updated:** 2009-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00099554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00099554, "Effectiveness and Safety of Enbrel® (Etanercept) in Rheumatoid Arthritis Subjects Who Have Failed Remicade® (Infliximab)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00099554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*